Research programme: palivizumab biosimilar - iBio
Latest Information Update: 16 Jul 2016
At a glance
- Originator iBio Inc
- Developer Fraunhofer USA Center for Molecular Biotechnology; iBio Inc
- Class Monoclonal antibodies
- Mechanism of Action Viral fusion protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Respiratory syncytial virus infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Respiratory-syncytial-virus-infections in USA (IM)
- 10 Apr 2012 Preclinical trials in Respiratory syncytial virus infections in USA (IM)